The findings also indicate that females and those without obesity-related complications may be more responsive to tirzepatide treatment, said researchers at the European Congress on Obesity (ECO) in Malaga, Spain. The study, led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that manufacture tirzepatide, is a continuation of the SURMOUNT-1 phase 3 trial of tirzepatide, a medication approved in the EU and USA for obesity and type 2 diabetes treatment.